Literature DB >> 23811963

Longitudinal changes in left ventricular stiffness: a community-based study.

Barry A Borlaug1, Margaret M Redfield, Vojtech Melenovsky, Garvan C Kane, Barry L Karon, Steven J Jacobsen, Richard J Rodeheffer.   

Abstract

BACKGROUND: Cross-sectional studies suggest that left ventricular (LV) and arterial elastance (stiffness) increase with age, but data examining longitudinal changes within human subjects are lacking. In addition, it remains unknown whether age-related LV stiffening is merely a reaction to arterial stiffening or caused by other processes. METHODS AND
RESULTS: Comprehensive echo-Doppler cardiography was performed in 1402 subjects participating in a randomly selected community-based study at 2 examinations separated by 4 years. From this population, 788 subjects had adequate paired data to determine LV end-systolic elastance (Ees), end-diastolic elastance (Eed), and effective arterial elastance. Throughout 4 years, blood pressure, arterial elastance, and LV mass decreased, coupled with significantly greater use of antihypertensive medications. However, despite reductions in arterial load, Ees increased by 14% (2.10±0.67-2.26±0.70 mm Hg/mL; P<0.0001) and Eed increased by 8% (0.13±0.03-0.14±0.04 mm Hg/mL; P<0.0001). Increases in Eed were greater in women than men, whereas Ees changes were similar. Age-related increases in Ees and Eed were correlated with changes in body weight, but were similar in subjects with or without cardiovascular disease. Changes in Ees were correlated with Eed (r=0.5; P<0.0001), but not with other measures of contractility, indicating that the increase in Ees was reflective of passive stiffening rather than enhanced systolic function.
CONCLUSIONS: Despite reductions in arterial load with medical therapy, LV systolic and diastolic stiffness increase over time in humans, particularly in women. In addition to blood pressure control, therapies targeting load-independent ventricular stiffening may be effective to treat and prevent age-associated cardiovascular diseases, such as heart failure.

Entities:  

Keywords:  aging; arterial stiffness; heart failure; hemodynamics; ventricular function

Mesh:

Substances:

Year:  2013        PMID: 23811963      PMCID: PMC3807873          DOI: 10.1161/CIRCHEARTFAILURE.113.000383

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  40 in total

1.  Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study.

Authors:  S R Ommen; R A Nishimura; C P Appleton; F A Miller; J K Oh; M M Redfield; A J Tajik
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Assessment of left ventricular diastolic function and recognition of diastolic heart failure.

Authors:  William H Gaasch; William C Little
Journal:  Circulation       Date:  2007-08-07       Impact factor: 29.690

4.  Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly.

Authors:  C H Chen; M Nakayama; E Nevo; B J Fetics; W L Maughan; D A Kass
Journal:  J Am Coll Cardiol       Date:  1998-11       Impact factor: 24.094

5.  Progression of left ventricular diastolic dysfunction and risk of heart failure.

Authors:  Garvan C Kane; Barry L Karon; Douglas W Mahoney; Margaret M Redfield; Veronique L Roger; John C Burnett; Steven J Jacobsen; Richard J Rodeheffer
Journal:  JAMA       Date:  2011-08-24       Impact factor: 56.272

6.  Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

Authors:  Linda B Piller; Sarah Baraniuk; Lara M Simpson; William C Cushman; Barry M Massie; Paula T Einhorn; Suzanne Oparil; Charles E Ford; James F Graumlich; Richard A Dart; David C Parish; Tamrat M Retta; Aloysius B Cuyjet; Syed Z Jafri; Curt D Furberg; Mohammad G Saklayen; Udho Thadani; Jeffrey L Probstfield; Barry R Davis
Journal:  Circulation       Date:  2011-10-03       Impact factor: 29.690

Review 7.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.

Authors:  Barry A Borlaug; Walter J Paulus
Journal:  Eur Heart J       Date:  2010-12-07       Impact factor: 29.983

8.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

9.  Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations.

Authors:  Miho Kawaguchi; Ilan Hay; Barry Fetics; David A Kass
Journal:  Circulation       Date:  2003-02-11       Impact factor: 29.690

10.  Gender-related differences in left ventricular chamber function.

Authors:  C S Hayward; W V Kalnins; R P Kelly
Journal:  Cardiovasc Res       Date:  2001-02-01       Impact factor: 10.787

View more
  57 in total

Review 1.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.

Authors:  Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

Review 2.  The pathophysiology of heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

Review 3.  Use of metformin in diseases of aging.

Authors:  John M Miles; Andrew D Rule; Barry A Borlaug
Journal:  Curr Diab Rep       Date:  2014-06       Impact factor: 4.810

4.  Prognostic value of revascularising viable myocardium in elderly patients with stable coronary artery disease and left ventricular dysfunction: a PET/CT study.

Authors:  Mehdi Namdar; Olivier Rager; Julien Priamo; Angela Frei; Stephane Noble; Gael Amzalag; Osman Ratib; René Nkoulou
Journal:  Int J Cardiovasc Imaging       Date:  2018-05-28       Impact factor: 2.357

5.  Five-year changes in cardiac structure and function in patients with rheumatoid arthritis compared with the general population.

Authors:  John M Davis; Grace Lin; Jae K Oh; Cynthia S Crowson; Sara J Achenbach; Terry M Therneau; Eric L Matteson; Richard J Rodeheffer; Sherine E Gabriel
Journal:  Int J Cardiol       Date:  2017-03-31       Impact factor: 4.164

Review 6.  Arterial Ventricular Uncoupling With Age and Disease and Recoupling With Exercise.

Authors:  Paul D Chantler
Journal:  Exerc Sport Sci Rev       Date:  2017-04       Impact factor: 6.230

Review 7.  Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium.

Authors:  Francesco S Loffredo; Andriana P Nikolova; James R Pancoast; Richard T Lee
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 8.  Heart failure with preserved ejection fraction in the elderly: scope of the problem.

Authors:  Bharathi Upadhya; George E Taffet; Che Ping Cheng; Dalane W Kitzman
Journal:  J Mol Cell Cardiol       Date:  2015-03-06       Impact factor: 5.000

9.  Left atrial function and mortality in the oldest old.

Authors:  David Leibowitz; Jonathan Koslowsky; Dan Gilon; Jeremy M Jacobs; Irit Stessman-Lande; Jochanan Stessman
Journal:  Clin Cardiol       Date:  2017-12-16       Impact factor: 2.882

10.  Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion.

Authors:  Yong Seon Choi; Ana Barbosa Marcondes de Mattos; Dan Shao; Tao Li; Miranda Nabben; Maengjo Kim; Wang Wang; Rong Tian; Stephen C Kolwicz
Journal:  J Mol Cell Cardiol       Date:  2016-09-28       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.